A5078778320- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- MRI in cancer diagnosis
- Nanoparticle-Based Drug Delivery
- Cancer, Hypoxia, and Metabolism
- Medical Imaging Techniques and Applications
- Cancer Research and Treatments
- Advanced MRI Techniques and Applications
- Gastric Cancer Management and Outcomes
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
Athinoula A. Martinos Center for Biomedical Imaging
2022-2024
Harvard University
2024
Massachusetts General Hospital
2022-2024
Pancreatic ductal adenocarcinoma (PDAC) is an invasive and rapidly progressive malignancy. A major challenge in patient management the lack of a reliable imaging tool to monitor tumor response treatment. Tumor-associated fibrosis characterized by high type I collagen hallmark PDAC, further increases neoadjuvant chemoradiotherapy (CRT). We hypothesized that molecular positron emission tomography (PET) using collagen-specific probe,
Abstract Purpose: One of the major challenges in management pancreatic ductal adenocarcinoma (PDAC) is lack a reliable imaging tool to monitor tumor response treatment. A high degree fibrosis, mainly collagen type I, has been recognized as hallmark PDAC, which further increases neoadjuvant chemoradiotherapy (CRT). This study introduces an image-guided paradigm for monitoring treatment using I specific PET probe, 68Ga-CBP8 mouse models and patients with PDAC. Methods: Subcutaneous human PDAC...
Abstract Neoadjuvant therapy is routinely used in pancreatic ductal adenocarcinoma (PDAC), but not all tumors respond to this treatment. Current clinical imaging techniques are able precisely evaluate and predict the response neoadjuvant therapies over several weeks. A strong fibrotic reaction a hallmark of positive response, during fibrogenesis, allysine residues formed on collagen proteins by action lysyl oxidases. Here, we report application an allysine-targeted molecular MRI probe, MnL3,...
Patients with advanced gastric cancer (GCa) have limited treatment options, and alternative approaches are necessary to improve their clinical outcomes. Because fibrin is abundant in tumors but not healthy tissues, we hypothesized that could be used as a high-concentration depot for high-energy beta-emitting cytotoxic radiopharmaceutical delivered tumor cells. We showed present 64 75% of primary 50 100% metastatic adenocarcinoma cores. First-in-human Cu-FBP8 fibrin–targeted positron emission...
<div>Abstract<p>Neoadjuvant therapy is routinely used in pancreatic ductal adenocarcinoma (PDAC), but not all tumors respond to this treatment. Current clinical imaging techniques are able precisely evaluate and predict the response neoadjuvant therapies over several weeks. A strong fibrotic reaction a hallmark of positive response, during fibrogenesis, allysine residues formed on collagen proteins by action lysyl oxidases. Here, we report application an allysine-targeted...
<p>Figure S4. The PDAC6 tumor percentage change of normalized signal intensity (%nSI, to an adjacent phantom) at 30 min p.i. probe (<i>n</i> = 4 for each group). One-way ANOVA with Tukey’s post hoc test, *<i>P</i><0.05, **<i>P</i> < 0.01, ns, not significant.</p>
<p>Figure S10. Quantification of manganese content in the 1319 tumor 60 minutes post-injection MnL3. After randomly assigning mice to vehicle or FOLFIRINOX group, MnL3 showed equivalent uptake (0.1 mmol/kg, i.v., min p.i., <i>n</i> = 5 for each Student’s <i>t</i>-test. ns: not significant).</p>
<p>Figure S7. MnL3 molecular MRI of PANC1 tumor-bearing mice before administration vehicle or FOLFIRINOX. After randomly assigning to FOLFIRINOX group, (0.1 mmol/kg, i.v., 60 min p.i.) showed equivalent tumor enhancement (<i>n</i> = 8 for each Student’s <i>t</i>-test, two-tailed, ns, not significant.).</p>
<p>Figure S4. The PDAC6 tumor percentage change of normalized signal intensity (%nSI, to an adjacent phantom) at 30 min p.i. probe (<i>n</i> = 4 for each group). One-way ANOVA with Tukey’s post hoc test, *<i>P</i><0.05, **<i>P</i> < 0.01, ns, not significant.</p>
<p>Figure S6. Quantification of manganese content in the PDAC6 tumor 60 minutes post-injection MnL3. MnL3 (0.1 mmol/kg, i.v., min p.i.) exhibited significantly higher uptake at 3 days (P = 0.05) and 7 (<i>P</i> 0.04) after initiation FOLFIRINOX treatment compared to untreated (One-way ANOVA with Tukey’s post hoc test, *<i>P</i><0.05, ns, not significant. <i>n</i> 6 for day 0 3, 5 7).</p>
<p>Figure S10. Quantification of manganese content in the 1319 tumor 60 minutes post-injection MnL3. After randomly assigning mice to vehicle or FOLFIRINOX group, MnL3 showed equivalent uptake (0.1 mmol/kg, i.v., min p.i., <i>n</i> = 5 for each Student’s <i>t</i>-test. ns: not significant).</p>
<p>Figure S1. Mass spectra of MnL3 solutions before and after reaction with butyraldehyde. (A) MS spectrum MnL3. [M + H]+ calcd for [C20H32MnN7O5], 505.2; found 505.0. (B) the product between butyraldehyde at pH 7.4 (PBS). [C24H38MnN7O5], 559.2; 559.5. (C) 6.5(PBS).</p>
<p>Figure S9. MnL3 molecular MRI of 1319 tumor-bearing mice before administration vehicle or FOLFIRINOX. After randomly assigning to the FOLFIRINOX group, showed equivalent tumor enhancement ( <i>n</i> = 4 for each Student’s <i>t</i>-test. ns: not significant).</p>
<p>Figure S3. Dynamic tumor %nSI in PDAC6 tumor-bearing mice after injection of MnL3 or MnL4. MnL4 (0.1 mmol/kg, i.v.) only produced transient signal enhancement injection, while persistent and higher tumors. (n = 4 for each group).</p>
<p>Figure S5. Immediate dynamic contrast enhanced (DCE) MRI in PDAC6 tumor with MnL4 performed before, at 3 days (1 dose FOLFIRNOX), or 7 (2 doses FOLFIRINOX) after the initiation of FOLFIRINOX treatment. Time course change normalized signal intensity acquired from DCE images as probe (0.1 mmol/kg, i.v., <i>n</i> = 4 for each group, data shown mean value 95% simultaneous confidence bands shaded regions). Data are superimposable time point measured, indicating no changes...
<p>Figure S2. Mass spectra of MnL4 before and after incubation with butyraldehyde. (A) MS spectrum MnL4. [M + H]+ calcd for [C25H39MnN6O7], 590.2; found 590.0. (B) did not react butyraldehyde at pH 7.4 (PBS). 590.0). (C) 6.5 590.0).</p>
<p>Figure S1. Mass spectra of MnL3 solutions before and after reaction with butyraldehyde. (A) MS spectrum MnL3. [M + H]+ calcd for [C20H32MnN7O5], 505.2; found 505.0. (B) the product between butyraldehyde at pH 7.4 (PBS). [C24H38MnN7O5], 559.2; 559.5. (C) 6.5(PBS).</p>
<p>Figure S8. Quantification of manganese content in the PANC1 tumor 60 minutes post-injection MnL3. MnL3 exhibited significantly higher uptake tumors treated with one dose FOLFIRINOX compared to untreated mice (0.1 mmol/kg, i.v., min p.i., <i>n</i> = 4 for each group, Student’s <i>t</i>-test, two-tailed, *<i>P</i><0.05).</p>
<p>Supplementary method, supplementary figure legends, and references.</p>
<p>Figure S7. MnL3 molecular MRI of PANC1 tumor-bearing mice before administration vehicle or FOLFIRINOX. After randomly assigning to FOLFIRINOX group, (0.1 mmol/kg, i.v., 60 min p.i.) showed equivalent tumor enhancement (<i>n</i> = 8 for each Student’s <i>t</i>-test, two-tailed, ns, not significant.).</p>
<p>Figure S2. Mass spectra of MnL4 before and after incubation with butyraldehyde. (A) MS spectrum MnL4. [M + H]+ calcd for [C25H39MnN6O7], 590.2; found 590.0. (B) did not react butyraldehyde at pH 7.4 (PBS). 590.0). (C) 6.5 590.0).</p>
<p>Figure S5. Immediate dynamic contrast enhanced (DCE) MRI in PDAC6 tumor with MnL4 performed before, at 3 days (1 dose FOLFIRNOX), or 7 (2 doses FOLFIRINOX) after the initiation of FOLFIRINOX treatment. Time course change normalized signal intensity acquired from DCE images as probe (0.1 mmol/kg, i.v., <i>n</i> = 4 for each group, data shown mean value 95% simultaneous confidence bands shaded regions). Data are superimposable time point measured, indicating no changes...
<div>Abstract<p>Neoadjuvant therapy is routinely used in pancreatic ductal adenocarcinoma (PDAC), but not all tumors respond to this treatment. Current clinical imaging techniques are able precisely evaluate and predict the response neoadjuvant therapies over several weeks. A strong fibrotic reaction a hallmark of positive response, during fibrogenesis, allysine residues formed on collagen proteins by action lysyl oxidases. Here, we report application an allysine-targeted...
<p>Figure S8. Quantification of manganese content in the PANC1 tumor 60 minutes post-injection MnL3. MnL3 exhibited significantly higher uptake tumors treated with one dose FOLFIRINOX compared to untreated mice (0.1 mmol/kg, i.v., min p.i., <i>n</i> = 4 for each group, Student’s <i>t</i>-test, two-tailed, *<i>P</i><0.05).</p>